OptiNose AS
1020 Stony Hill Road
Third Floor, Suite 300
Yardley
Pennsylvania
19067
United States
Tel: 267-364-3500
Fax: 267-395-2119
Website: http://www.optinose.com/
Email: info@optinose.com
99 articles with OptiNose AS
-
OptiNose AS Announces Positive Results Of Phase III Trial For OPN-375
6/24/2015
-
OptiNose AS To Present At Innovations In Healthcare Executive Forum
3/30/2015
-
OptiNose AS To Present At Nasal And Respiratory Drug Delivery Conferences
3/19/2015
-
OptiNose AS To Present At The 35th Annual Cowen and Company Healthcare Conference
2/23/2015
-
OptiNose AS Announces Publication Of Pivotal Phase 3 Results For Investigational Migraine Treatment Developed By Optinose Using Bi-Directional™ Breath Powered™ Technology
10/31/2014
-
OptiNose AS Completes Series C-1 Financing
8/4/2014
-
OptiNose AS Expands Senior Management Team With Three Key Appointments In Core Business Areas Of Operations, Regulatory Affairs And Commercialization
6/12/2014
-
OptiNose AS Presents Positive Results From Phase 3 COMPASS Study
6/10/2014
-
OptiNose AS Announces FDA Acceptance Of New Drug Application For AVP-825 For The Acute Treatment Of Migraine
3/27/2014
-
OptiNose AS to Present Data Highlighting New Migraine Treatment at International Headache Congress
6/28/2013
-
OptiNose AS Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
2/9/2012
-
OptiNose AS Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology
2/3/2012
-
OptiNose AS Selects BioClinica, Inc.'s Trident IWR, Optimizer and Imaging Core Lab Solutions
9/8/2011
-
OptiNose AS Standardizes on Medidata Solutions, Inc. Rave Clinical Technology
8/30/2011
-
OptiNose AS Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application
5/23/2011
-
OptiNose AS Receives Nearly $489,000 Grant Award under U.S. Government Qualifying Therapeutic Discovery Project Program
11/3/2010
-
Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose AS's Novel Drug Delivery Technology
10/28/2010
-
OptiNose AS Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology
8/10/2010
-
Avista Capital Partners Commits $48.5 Million to OptiNose AS to Develop an Innovative Nasal Drug Delivery Technology Slated to Begin Phase III Trials
6/8/2010